Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 48

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 48
---
 practices are not reasonably likely to have a material adverse effect on us.

Certain Post-Fiscal Year-End 2024 Actions

Equity Awards

In February 2025, the compensation committee and our board of directors, as applicable, approved grants of option and RSU awards under our 2020 Plan to Mr. Segal and Dr. Zinda, effective as of March 4, 2025, the second business day after publication of our Annual Report on Form 10-K for the year ended December 31, 2024, including (i) to Mr. Segal, (a) option awards to purchase 487,000 common shares, consisting of an option award to purchase 237,000 shares as part of Mr. Segal’s annual equity-based incentive compensation and a performance-based option award to purchase 250,000 shares for retention purposes, and (b) 40,000 RSUs, and (ii) to Dr. Zinda, (a) option awards to purchase 160,000 common shares, consisting of an option award to purchase 85,000 shares as part of Dr. Zinda’s annual equity-based incentive compensation and an option award to purchase 75,000 shares for retention purposes, and (b) 14,000 RSUs. The option awards representing Mr. Segal’s and Dr. Zinda’s annual equity- incentive compensation were subject to vesting over a four-year period, with 25% of the shares subject to each such award vesting on March 4, 2026, with the remainder of the award vesting monthly in equal installments over the following 36 months such that the award would vest in full on March 4, 2029, subject to the named executive officer’s continuous service with us as of each such vesting date. Mr. Segal’s performance-based award would have vested as to 100% of the shares subject to such award upon the consummation of a strategic transaction whereby 100% of the voting securities of the Company and/or substantially all of the Company’s assets are acquired by a major pharmaceutical company, as determined and certified by the board of directors, subject to Mr. Segal’s continuous service. Dr. Zinda’s retention option award will vest as to 100% of the shares subject to such award on the one-year anniversary of the grant or the date of involuntary termination of continuous service, whichever is sooner. The RSU awards will vest over a three-year period, with one-third of